Tag: COVID-19
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
2. Treatment with tocilizumab did not improve survival among patients.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe...
1. In Washington State, pregnant patients were found to be at a higher risk of SARS-CoV-2 infection.
2. Results were more pronounced if patients belonged to a non-white racial or ethnic group or received their care in a language other than English.
Evidence Level Rating: 2 (Good)
As the COVID-19 pandemic continues to...
Heterologous recombinant adenovirus-based COVID-19 vaccine (Gam-COVID-Vac) is tolerable and highly efficacious
Neel Mistry -
1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%.
2. In the vaccine group, there were no confirmed cases of moderate or severe COVID-19 21 days after the first dose.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Global efforts to develop safe and effective vaccines for COVID-19 prevention are...
1. Treatment with tocilizumab and sarilumab increased the number of days without respiratory or cardiovascular organ support in patients with COVID-19.
2. Interleukin-6 receptor antagonists improved in-hospital survival for patients diagnosed with COVID-19 and receiving organ support in the ICU.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Thus far, only glucocorticoids have...
Novel SARS-CoV-2 vaccine candidate SCB-2019 offers good safety profile and elicits strong humoral responses
Michael Pratte -
1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults.
2. SCB-2019 adjuvanted with AS03 or CpG/Alum elicited strong humoral and cellular responses.
Evidence Rating Level: 1 (Excellent)
Study Rundown: As the global pandemic of SARS-CoV-2 (COVID-19) continues to ravage healthcare systems around the world, the effort to produce...
Polypharmacy in non-care home residents strongly associated with higher rates of severe COVID-19
Kathleen Lau -
1. Polypharmacy in non-care home residents was strongly associated with higher rates of severe COVID-19.
Evidence Rating Level: 3 (Average)
Resistant hypertension, which is uncontrolled despite maximal medical therapy, affects up to 10% of patients diagnosed with hypertension. Renal artery denervation has been demonstrated in a number of smaller, nonrandomized and/or...
1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated with usual care.
2. Dexamethasone treatment had a shorter duration in hospital stay compared to the usual care group.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Although the majority of coronavirus disease...
ACEi and ARB use not associated with increased risk of COVID-19 hospitalization or mortality
Kathleen Lau -
1. There is no association between ACE inhibitor or ARB use compared with other antihypertensives for risk of COVID-19 hospitalization for outpatients.
2. There is no association between ACE inhibitor or ARB use compared with other antihypertensives for increased mortality risk in patients hospitalized with diagnosis of COVID-19.
Evidence...
COVID-19 lockdowns associated with increased quiet time and less spoken communication for children with cochlear implants
Davy Lau -
1. During the COVID-19 pandemic lockdowns, schoolchildren with cochlear implants were exposed to more quiet time and less spoken communication, with a speech:quiet ratio of 0.9:1.0 during the lockdowns, compared to a 1.6:1.0 ratio prior to lockdowns.
2. Children with fewer household members did not experience less spoken communication, but...
Diagnosis and treatment of iron deficiency in heart failure: OFICSel study by the French Heart Failure Working Group
1. Cardiologists were under-testing, against guidelines, for iron deficiency in heart failure patients, likely resulting in under-diagnosing and under-treatment.
Evidence Rating Level: 2 (Good)
One in every two patients with heart failure (HF) also...